Journal of bone oncology · 2018 · 29 citations · 20 references
MedicineOncologyPharmacologyImmunotherapyTumor ImmunologyTumor MicroenvironmentCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsImmune CheckpointsImmunotherapy For Solid TumorsMyeloid-derived Suppressor CellsCheckpoint Inhibitor AntibodiesCytotoxic T-lymphocyte Antigen 4 (Ctla-4) PathwayCytotoxic T-lymphocyte-associated Protein 4 InhibitorsImmune Checkpoint Inhibitor TherapyImmunosuppressive MicroenvironmentMyeloid-derived Suppressor Cell InfiltrationPi3k InhibitorsSyngeneic Tumor Models
T cells. Our results demonstrated that addition of SNA to anti-PD1 significantly altered infiltration and function of innate immune cells, providing the rationale for combination therapy in patients with osteosarcoma through inhibiting the function of MDSCs with a selective PI3Kδ/γ inhibitor to enhance responses to immune checkpoint blockade.
20
PI3Kγ is a molecular switch that controls immune suppression
Megan M. Kaneda, Karen Messer, Natacha Ralainirina et al. · Nature · 2016 · 1.2K citations
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
Olivier De Henau, Matthew Rausch, David A. Winkler et al. · Nature · 2016 · 865 citations
Medicine, Cancer Biology, Oncology +14
Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy
Steven L. Highfill, Yongzhi Cui, Amber Giles et al. · Science Translational Medicine · 2014 · 756 citations · Full text
Medicine, Immunology, Oncology +16
Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
Khaled Ali, Dalya R. Soond, Roberto Piñeiro et al. · Nature · 2014 · 543 citations · Full text
Life Sciences, Immunology, Oncology +10